RxDoctor Payments Data

Sachin Shah, MD

Interventional Pain Medicine · Somerset, NJNPI 1265665228

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,626 of the $3,856 with a category attached, or 68.1%. 17 manufacturers reported payments, led by Medtronic at 54.8% of the total. Reporting peaked in 2021 at $1,982 and has fallen 91.6% since, to $167 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in NJ, where the typical reported total is $3,760.

$3,856in general payments, 2019–2025

Across 124 payments — averaging $31.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Boston Scientific$679
  • Biotronik NRO, Inc.$319
  • Nevro Corp.$226
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$111
  • Collegium Pharmaceutical, Inc.$86
  • plus $324 from 11 others

What the payments were for

  • Speaking & faculty fees$1,23032%
  • Food & beverage$2,62668%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,856 in reported general payments places this provider in the 50th percentile of 82 interventional pain medicine providers in New Jersey.

See all interventional pain medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$121,820
Medicare patients
200
Services billed
1,727

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate30$19,619
OxycontinOxycodone Hcl14$14,720
Fentanyl24$4,935
Oxycodone Hcl262$4,544
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen206$4,021
Morphine Sulfate ErMorphine Sulfate40$1,344
Gabapentin107$1,121
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen43$1,001
Duloxetine Hcl19$672
Tizanidine Hcl62$570
Morphine Sulfate22$546
Tramadol Hcl125$521
Methadone Hcl37$513
Pregabalin31$470
Diclofenac Sodium13$319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$86$19,61930 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 82 interventional pain medicine providers in New Jersey.

Other interventional pain medicine in Somerset

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →